Effect of Macrolide and Fluoroquinolone Antibacterials on the Risk of Ventricular Arrhythmia and Cardiac Arrest: an Observational Study in Italy Using Case-control, Case-crossover and Case-time-control Designs

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2009 Feb 25

PMID 19236122

Citations 24

Authors

Antonella Zambon

Hernan Polo Friz

Paolo Contiero

Giovanni Corrao

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the effect of macrolide and fluoroquinolone antibacterials on the onset of ventricular arrhythmia and cardiac arrest using three different observational designs.

Methods: A population-based case-control study was performed by linking automated databases from the Varese Province of Italy. Cases were all subjects who experienced ventricular arrhythmia or cardiac arrest from July 1998 to December 2003. For each case, up to ten controls were randomly selected after matching for sex, age, practitioner and date of arrhythmia onset. The use of macrolides and fluoroquinolones during two time windows denoted as recent and referent intervals was ascertained. Odds ratios were estimated using case-control, case-crossover and case-time-control approaches.

Results: 1275 cases and 9189 controls met the inclusion criteria. Adjusted odds ratios (and corresponding 95% CIs) associated with recent exposure to macrolides were 2.13 (1.34, 3.39), 1.70 (0.88, 3.26) and 1.62 (0.78, 3.34) by using case-control, case-crossover and case-time-control designs, respectively. The corresponding estimates for fluoroquinolones were 3.58 (2.51, 5.12), 1.98 (1.19, 3.29) and 1.59 (0.88, 2.87), respectively.

Conclusions: Three observational study designs each using entirely different sets of controls consistently showed that recent use of macrolide and fluoroquinolone antibacterials may be associated with increased risk of ventricular arrhythmia and cardiac arrest.

Citing Articles

Antimicrobial Resistance and Sports: The Scope of the Problem, Implications for Athletes' Health and Avenues for Collaborative Public Health Action.

Ozegic O, Bedenic B, Sternak S, Sviben M, Talapko J, Pazur I Antibiotics (Basel). 2024; 13(3).

PMID: 38534667 PMC: 10967618. DOI: 10.3390/antibiotics13030232.

Fluoroquinolones do not provide added risk of out-of-hospital cardiac arrest: a nationwide study.

Ellenardottir V, Coronel R, Folke F, Halili A, Arulmurugananthavadivel A, Parveen S Open Heart. 2024; 11(1).

PMID: 38216172 PMC: 10806456. DOI: 10.1136/openhrt-2023-002520.

Respiratory Infections in the Aging Lung: Implications for Diagnosis, Therapy, and Prevention.

Hader A, Kose-Vogel N, Schulz L, Mlynska L, Hornung F, Hagel S Aging Dis. 2023; 14(4):1091-1104.

PMID: 37163442 PMC: 10389836. DOI: 10.14336/AD.2023.0329.

Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study.

Yadegarynia D, Tehrani S, Nejad Maghsoudi F, Shojaeian F, Keyvanfar A Iran J Microbiol. 2023; 14(4):458-465.

PMID: 36721509 PMC: 9867629. DOI: 10.18502/ijm.v14i4.10231.

Drug-induced Sudden Death: A Scoping Review.

Amaro-Hosey K, Castells X, Blanco-Silvente L, Loma-Osorio P, Capella D Curr Drug Saf. 2022; 18(3):307-317.

PMID: 35619276 PMC: 10258916. DOI: 10.2174/1574886317666220525115232.

References

Singh S, Patrick J . Antiarrhythmic Drugs. Curr Treat Options Cardiovasc Med. 2004; 6(5):357-364. DOI: 10.1007/s11936-004-0019-2. View

Schneider M, Gange S, Margolick J, Detels R, Chmiel J, Rinaldo C . Application of case-crossover and case-time-control study designs in analyses of time-varying predictors of T-cell homeostasis failure. Ann Epidemiol. 2005; 15(2):137-44. DOI: 10.1016/j.annepidem.2004.05.002. View

Corrao G, Botteri E, Bertu L, Zambon A, Favilli S . Exploring the effect of transient exposure on the risk of acute events by means of time-window designs: an application to fluoroquinolone antibacterials and arrhythmia. Pharmacoepidemiol Drug Saf. 2005; 15(1):31-7. DOI: 10.1002/pds.1125. View

Smeeth L, Thomas S, Hall A, Hubbard R, Farrington P, Vallance P . Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351(25):2611-8. DOI: 10.1056/NEJMoa041747. View

Matsunaga N, Oki Y, Prigollini A . A case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003; 116(1185):U666. View

Leufkens H, Urquhart J . Variability in patterns of drug usage. J Pharm Pharmacol. 1994; 46 Suppl 1:433-7. View

Bagnardi V, Botteri E, Corrao G . Empirical-Bayes adjustment improved conventional estimates in postmarketing drug-safety studies. J Clin Epidemiol. 2006; 59(11):1162-8. DOI: 10.1016/j.jclinepi.2006.02.019. View

Suissa S . The case-time-control design. Epidemiology. 1995; 6(3):248-53. DOI: 10.1097/00001648-199505000-00010. View

Suissa S . The case-time-control design: further assumptions and conditions. Epidemiology. 1998; 9(4):441-5. View

10.

Smeeth L, Donnan P, Cook D . The use of primary care databases: case-control and case-only designs. Fam Pract. 2006; 23(5):597-604. DOI: 10.1093/fampra/cml025. View

11.

Maclure M . The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991; 133(2):144-53. DOI: 10.1093/oxfordjournals.aje.a115853. View

12.

De Bruin M, Hoes A, Leufkens H . QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol. 2002; 91(1):59-62. DOI: 10.1016/s0002-9149(02)02998-3. View

13.

Corrao G, Zambon A, Faini S, Bagnardi V, Leoni O, Suissa S . Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol. 2005; 58(1):92-7. DOI: 10.1016/j.jclinepi.2004.04.013. View

14.

Salas M, Hofman A, Stricker B . Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999; 149(11):981-3. DOI: 10.1093/oxfordjournals.aje.a009758. View

15.

Antzelevitch C . Cellular basis and mechanism underlying normal and abnormal myocardial repolarization and arrhythmogenesis. Ann Med. 2004; 36 Suppl 1:5-14. DOI: 10.1080/17431380410032553. View

16.

Staffa J, Jones J, Gable C, Verspeelt J, Amery W . Risk of selected serious cardiac events among new users of antihistamines. Clin Ther. 1995; 17(6):1062-77. DOI: 10.1016/0149-2918(95)80085-9. View

17.

Zabel M, Hohnloser S, Behrens S, Li Y, Woosley R, Franz M . Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol. 1997; 8(10):1148-58. DOI: 10.1111/j.1540-8167.1997.tb01001.x. View

18.

Hernandez-Diaz S, Hernan M, Meyer K, Werler M, Mitchell A . Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol. 2003; 158(4):385-91. DOI: 10.1093/aje/kwg144. View

19.

Ray W, Murray K, Meredith S, Narasimhulu S, Hall K, Stein C . Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004; 351(11):1089-96. DOI: 10.1056/NEJMoa040582. View

20.

Shaffer D, Singer S, Korvick J, Honig P . Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002; 35(2):197-200. DOI: 10.1086/340861. View